Kancera AB EBITDA vs. Current Ratio

KAN Stock  SEK 1.52  0.09  6.29%   
Based on the measurements of profitability obtained from Kancera AB's financial statements, Kancera AB may not be well positioned to generate adequate gross income at the moment. It has a very high risk of underperforming in June. Profitability indicators assess Kancera AB's ability to earn profits and add value for shareholders.
For Kancera AB profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Kancera AB to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Kancera AB utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Kancera AB's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Kancera AB over time as well as its relative position and ranking within its peers.
  
Check out Correlation Analysis.
Please note, there is a significant difference between Kancera AB's value and its price as these two are different measures arrived at by different means. Investors typically determine if Kancera AB is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kancera AB's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Kancera AB Current Ratio vs. EBITDA Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Kancera AB's current stock value. Our valuation model uses many indicators to compare Kancera AB value to that of its competitors to determine the firm's financial worth.
Kancera AB is rated fourth overall in ebitda category among related companies. It is rated third overall in current ratio category among related companies . Comparative valuation analysis is a catch-all model that can be used if you cannot value Kancera AB by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Kancera AB's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Kancera AB's earnings, one of the primary drivers of an investment's value.

Kancera Current Ratio vs. EBITDA

EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.

Kancera AB

EBITDA

 = 

Revenue

-

Basic Expenses

 = 
(45.35 M)
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.

Kancera AB

Current Ratio

 = 

Current Asset

Current Liabilities

 = 
2.11 X
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).

Kancera AB Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Kancera AB, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Kancera AB will eventually generate negative long term returns. The profitability progress is the general direction of Kancera AB's change in net profit over the period of time. It can combine multiple indicators of Kancera AB, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Kancera AB , a biotechnology company, engages in the development and sale of drug candidates to pharmaceutical companies in Sweden and internationally. The company was founded in 2010 and is based in Solna, Sweden. Kancera AB operates under Pharmaceuticals And Biosciences classification in Sweden and is traded on Stockholm Stock Exchange.

Kancera Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Kancera AB. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Kancera AB position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Kancera AB's important profitability drivers and their relationship over time.

Use Kancera AB in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Kancera AB position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Kancera AB will appreciate offsetting losses from the drop in the long position's value.

Kancera AB Pair Trading

Kancera AB Pair Trading Analysis

The ability to find closely correlated positions to Kancera AB could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Kancera AB when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Kancera AB - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Kancera AB to buy it.
The correlation of Kancera AB is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Kancera AB moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Kancera AB moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Kancera AB can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Kancera AB position

In addition to having Kancera AB in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Soft Drinks Thematic Idea Now

Soft Drinks
Soft Drinks Theme
Entities manufacturing and distributing non alcoholic beverages across different markets. The Soft Drinks theme has 47 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Soft Drinks Theme or any other thematic opportunities.
View All  Next Launch
Check out Correlation Analysis.
You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.

Complementary Tools for Kancera Stock analysis

When running Kancera AB's price analysis, check to measure Kancera AB's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kancera AB is operating at the current time. Most of Kancera AB's value examination focuses on studying past and present price action to predict the probability of Kancera AB's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kancera AB's price. Additionally, you may evaluate how the addition of Kancera AB to your portfolios can decrease your overall portfolio volatility.
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
To fully project Kancera AB's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Kancera AB at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Kancera AB's income statement, its balance sheet, and the statement of cash flows.
Potential Kancera AB investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Kancera AB investors may work on each financial statement separately, they are all related. The changes in Kancera AB's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Kancera AB's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.